J&J approaches Actelion

Johnson & Johnson (NYSE:JNJ) is reportedly in preliminary discussions to buy Actelion Pharmaceuticals (VTX:ATLN) in a deal estimated to be as high as $247 (250 Swiss francs) per share, although the European biotech said there is no guarantee the deal will go through.

J&J’s CEO Alex Gorsky said this year that the company is interested in deals to expand its medical device and pharmaceuticals segments, according to Reuters, evidenced by its $4.33 billion buy of Abbott Laboratories’ eye care business in September.

Get the full story at our sister site, Drug Delivery Business News.

The post J&J approaches Actelion appeared first on MassDevice.

from MassDevice http://ift.tt/2gOOjNv